Gammagard Liquid® (immune globulin infusion [human] 10% solution) – New indication
January 22, 2024 - Takeda announced the FDA approval of Gammagard Liquid (immune globulin infusion [human] 10% solution), as a therapy to improve neuromuscular disability and impairment in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Top